Dolutegravir is a integrase inhibitor used for the treatment of HIV infection. In combination with abacavir and lamivudine it is superior to raltegravir in this combination. This may be because its use is not always associated with resistance to raltegravir-associated resistence mutations.
- HIV infection as part of combination therapy
- Triumeq® is a combination of dolutegravir, abacavir sulfate and lamivudine
- Juluca® is a combination of dolutegravir and rilpivirine
Cautions and Interactions
- Deterioration liver function in patients co-infected with hepatitis B or C
- ↑ Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013 Jul 2.(Epub ahead of print) (Link to article – subscription may be required.)